Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer.
Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer.
复制标题
CD8 T淋巴细胞上程序性细胞死亡蛋白1表达在胰腺癌中的预后价值
DOI：
10.1038/s41598-017-08479-9
复制
发表时间：
2017-08-10
影响因子：
4.6
通讯作者：
Cao L
中科院分区：
文献类型：
--
作者：
Shen T;Zhou L;Shen H;Shi C;Jia S;Ding GP;Cao L
胰腺癌是最具侵袭性的恶性肿瘤之一，具有高度免疫抑制的肿瘤微环境。免疫检查点阻断在许多恶性肿瘤中导致了显著和持久的客观反应，在传统的手术、放疗和化疗方式失败的地方，靶向程序性细胞死亡蛋白1 （PD-1）的基于抗体的策略显示出希望。在本研究中，我们探讨了CD8+外周T淋巴细胞或肿瘤浸润T淋巴细胞（TILs）在胰腺导管腺癌（PDAC）中PD-1蛋白表达的临床价值。CD8+ TILs上PD-1蛋白的表达与总生存率及临床分期、N分型、M分型等临床病理特征相关。PD-1蛋白在外周血CD8+ T细胞上的表达也有类似的结果，而其在外周血CD4+ T细胞上的表达无统计学意义。比较术前和术后4周外周血CD8+ T细胞表达PD-1蛋白水平，发现术前和术后外周血PD-1表达状态无变化。我们的研究结果表明，外周或肿瘤浸润的CD8+ T细胞表达的PD-1蛋白是PDAC诊断和预后的一个有希望的生物标志物，可能有助于指导未来的免疫治疗。
Pancreatic cancer is one of the most aggressive malignancies and has a highly immunosuppressive tumour microenvironment. Immune checkpoint blockade has led to remarkable and durable objective responses in a number of malignancies and antibody-based strategies targeting programmed cell death protein 1 (PD-1) are showing promise where traditional modalities of surgery, radiotherapy, and chemotherapy have failed. In this study, we examined the clinical value of PD-1 protein expression by CD8+ peripheral T lymphocytes or tumour-infiltrating T lymphocytes (TILs) in pancreatic ductal adenocarcinoma (PDAC). Expression of PD-1 protein on CD8+ TILs correlated with overall survival and clinicopathological characteristics such as clinical stage, N classification, and M classification. Similar findings were observed for the expression of PD-1 protein on peripheral CD8+ T cells, whereas its expression on peripheral CD4+ T cells showed no significance. Comparison of the levels of PD-1 protein expressed by peripheral CD8+ T cells before and 4 weeks after surgery indicated that preoperative and postoperative status of peripheral PD-1 expression was unchanged. Our findings showed that PD-1 protein expressed by peripheral or tumour-infiltrated CD8+ T cells was a promising biomarker for diagnosis and prognosis in PDAC and might help guide future immunotherapies.
登录
查看更多内容
影响因子：
82.9
作者：
Gros A;Parkhurst MR;Tran E;Pasetto A;Robbins PF;Ilyas S;Prickett TD;Gartner JJ;Crystal JS;Roberts IM;Trebska-McGowan K;Wunderlich JR;Yang JC;Rosenberg SA
通讯作者：
Rosenberg SA
影响因子：
2.9
作者：
Liu FH;Wang C;Xing YL;Wu JH;Tang Y
通讯作者：
Tang Y
DOI：
10.1056/nejmoa1200694
发表时间：
2012-06-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Brahmer JR;Tykodi SS;Chow LQ;Hwu WJ;Topalian SL;Hwu P;Drake CG;Camacho LH;Kauh J;Odunsi K;Pitot HC;Hamid O;Bhatia S;Martins R;Eaton K;Chen S;Salay TM;Alaparthy S;Grosso JF;Korman AJ;Parker SM;Agrawal S;Goldberg SM;Pardoll DM;Gupta A;Wigginton JM
通讯作者：
Wigginton JM
影响因子：
64.8
作者：
Herbst RS;Soria JC;Kowanetz M;Fine GD;Hamid O;Gordon MS;Sosman JA;McDermott DF;Powderly JD;Gettinger SN;Kohrt HE;Horn L;Lawrence DP;Rost S;Leabman M;Xiao Y;Mokatrin A;Koeppen H;Hegde PS;Mellman I;Chen DS;Hodi FS
通讯作者：
Hodi FS
影响因子：
11.5
作者：
Nomi, Takeo;Sho, Masayuki;Nakajima, Yoshiyuki
通讯作者：
Nakajima, Yoshiyuki